SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?

Core Insights - Investors in the Medical - Drugs sector may consider Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN) as potential undervalued stocks [1] Valuation Metrics - Sandoz Group AG has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Stevanato Group, which has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for SDZNY is 21.93, while STVN has a forward P/E of 38.10, suggesting SDZNY is more attractively priced [5] - SDZNY has a PEG ratio of 1.17, compared to STVN's PEG ratio of 2.17, indicating SDZNY's expected earnings growth is more favorable [5] - The P/B ratio for SDZNY is 3.56, while STVN's P/B ratio is 3.98, further supporting SDZNY's valuation advantage [6] - Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, indicating SDZNY is currently the superior value option [6]